TipHub

431.1

-1.34 -0.31%

As of 28 Jul 2026 · delayed

NSE Listed · Healthcare

Biocon Limited (BIOCON)

Volume: 34,29,52352W Range:331447.15
Key Ratios
Checked 9h ago
Market Cap₹70,196 Cr
Current Price₹431.1
Previous Close₹432.44
High / Low (52w)₹447.15 / ₹331
Volume34,29,523
Avg Vol (1W)
Avg Vol (1M)
Stock P/E153.42
Book Value₹210.14
Dividend Yield12%
ROE1.15%
ROA1.73%
Revenue (TTM)
Revenue Growth
Profit Margin
Total Debt
Shares Outstanding
Face Value
EPS (TTM)₹2.81
P/B2.05
Debt / Equity42.15
50 DMA₹422.86
200 DMA₹390.92
Day change-0.31%
Price Chart
431.1 10.28% · 1Y
4413404.3Cr
2025-07-31
2026-07-28

20-day avg volume: 67.9L shares

Pros
  • Pays a dividend yield of 12.0%.
  • Revenue grew 11% YoY.
Cons
  • Stock trades at a high P/E of 153.
Quarterly Results
MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025
Revenue₹4,484 Cr₹4,173 Cr₹4,263 Cr₹3,910 Cr₹4,358 Cr
EBITDA₹992 Cr₹657 Cr₹917 Cr₹829 Cr₹1,136 Cr
Net Profit₹126 Cr₹144 Cr₹85 Cr₹31 Cr₹345 Cr
EPS0.791.070.650.262.87
Profit & Loss (Annual)
MetricMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹16,780 Cr₹15,052 Cr₹14,196 Cr₹10,934 Cr
EBITDA₹3,369 Cr₹4,461 Cr₹4,068 Cr₹2,429 Cr
Net Profit₹386 Cr₹1,013 Cr₹1,023 Cr₹463 Cr
EPS2.828.468.543.87
Balance Sheet
MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Total Assets₹63,651 Cr₹58,797 Cr₹56,071 Cr₹52,043 Cr
Total Liabilities₹27,029 Cr₹31,085 Cr₹30,796 Cr₹29,554 Cr
Equity₹34,032 Cr₹21,644 Cr₹19,784 Cr₹17,867 Cr
Total Debt₹15,434 Cr₹18,362 Cr₹16,277 Cr₹18,019 Cr
Cash Flow
MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Operating₹1,994 Cr₹4,061 Cr₹2,954 Cr₹1,853 Cr
Investing₹-2,082 Cr₹-234 Cr₹-1,004 Cr₹-14,282 Cr
Financing₹-924 Cr₹-1,854 Cr₹-2,333 Cr₹13,049 Cr
Free Cash Flow₹82 Cr₹1,718 Cr₹1,022 Cr₹126 Cr
Shareholding
Promoter 53.76% Institutions 26.3% Public 19.94%
About Biocon Limited

Healthcare · Biotechnology

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

www.biocon.com
Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search